SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study
About this study
Prospective trials performed on type 2 diabetes patients without established cardiovascular disease has shown that SGLT2 inhibitors reduce cardiovascular risk. No studies have yet examined the occurrence of cardiovascular disease in patients with acute myocardial infarction. The investigators designed the current study to evaluate the most ideal oral hypoglycemic agent in type 2 diabetes patients undergoing percutaneous coronary intervention for acute myocardial infarction. The investigators hypothesize that the use of SGLT-2 inhibitors will reduce cardiovascular events and modify left ventricular remodeling after myocardial infarctions.
- Condition
- Myocardial Infarction, Diabetes Mellitus, Type 2
- Tested
- SGLT2 inhibitor
- Sponsor
- Kiyuk Chang
Who can join
- Age
- 19 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 5
- Minimum age: 19 years
- Study condition: Myocardial Infarction, Diabetes Mellitus, Type 2
- Acute myocardial infarction who were treated with percutaneous coronary intervention
- Type 2 diabetes mellitus
- Started SGLT2 inhibitors \<1 month before/after PCI
Exclusion 4
- Type 1 diabetes mellitus
- Insulin / GLP-1 analogue users
- Previous users of SGLT2 inhibitors
- Pregnancy
Where
1 site, 1 recruiting
Seoul St. Mary's Hospital
Seoul, South Korea
Contact
-
Kiyuk Chang, MD, PhD
82-2-2258-1139 kiyuk@catholic.ac.kr
Potential match only. Final eligibility is determined by the study team.